TRDA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 7.58%

Insider Buying (Last 12 Months): $119,271.76

Insider Selling (Last 12 Months): $1,253,326.80

Entrada Therapeutics Insider Trading History Chart

Entrada Therapeutics Share Price & Price History

^$14.05

▲ +0.17 (1.22%)

As of 05/8/2024 01:00 AM ET

Days: 30 | 90 | 365

Elon to Transform U.S. Economy?

From Porter & Company | Ad

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

Entrada Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/8/2024	Peter S Kim	Director	Buy	2,600	$13.57	$35,282.00	62,936
3/28/2024	Peter S Kim	Director	Buy	1,512	$13.75	$20,790.00	60,336
3/25/2024	Peter S Kim	Director	Buy	3,180	$13.36	$42,484.80	56,074
3/21/2024	Peter S Kim	Director	Buy	704	$13.24	$9,320.96	49,776
3/19/2024	Peter S Kim	Director	Buy	900	$12.66	$11,394.00	47,944
2/15/2024	Dipal Doshi	CEO	Sell	1,000	$15.00	$15,000.00	243,279
1/16/2024	Dipal Doshi	CEO	Sell	1,000	$15.99	$15,990.00	244,279
12/26/2023	Kory James Wentworth	CFO	Sell	94	$16.67	$1,566.98	49,571
12/22/2023	Kory James Wentworth	CFO	Sell	10,206	$15.69	$160,132.14	49,571
12/20/2023	Dipal Doshi	CEO	Sell	1,000	$15.00	$15,000.00	245,279
11/13/2023	Dipal Doshi	CEO	Sell	1,000	$16.23	$16,230.00	246,279
10/17/2023	Dipal Doshi	CEO	Sell	1,000	$15.00	$15,000.00	247,279
9/13/2023	Dipal Doshi	CEO	Sell	1,000	$15.00	$15,000.00	248,279
9/6/2023	Kory James Wentworth	CFO	Sell	950	$13.48	$12,806.00	49,571
9/6/2023	Nathan J Dowden	COO	Sell	972	$13.47	$13,092.84	48,168
9/6/2023	Nerissa Kreher	Insider	Sell	892	$13.48	$12,024.16	40,037
8/14/2023	Dipal Doshi	CEO	Sell	1,000	$15.67	$15,670.00	201,069
8/4/2023	Nerissa Kreher	Insider	Sell	6,898	$14.14	$97,537.72	27,130
8/2/2023	Nerissa Kreher	Insider	Sell	10,348	$15.19	$157,186.12	27,130
7/11/2023	Kory James Wentworth	CFO	Sell	3,884	$18.00	$69,912.00	36,747
7/10/2023	Natarajan Sethuraman	Insider	Sell	3,026	$18.00	$54,468.00	168,299
7/10/2023	Nathan J Dowden	COO	Sell	3,200	$18.00	$57,600.00	39,273
6/22/2023	Nathan J Dowden	COO	Sell	7,097	$16.02	$113,693.94	42,473
6/21/2023	Kory James Wentworth	CFO	Sell	17,500	$15.01	$262,675.00	27,957
6/20/2023	Nathan J Dowden	COO	Sell	8,885	$14.94	$132,741.90	49,570
4/27/2023	Dipal Doshi	CEO	Sell	2,000	$13.71	$27,420.00	202,069
4/17/2023	Dipal Doshi	CEO	Sell	2,092	$18.01	$37,676.92	204,069
4/17/2023	Natarajan Sethuraman	Insider	Sell	3,961	$18.00	$71,298.00	171,325
3/27/2023	Dipal Doshi	CEO	Sell	2,000	$14.72	$29,440.00	255,811
1/27/2023	Dipal Doshi	CEO	Sell	2,000	$12.00	$24,000.00	163,835
1/9/2023	Dipal Doshi	CEO	Sell	2,410	$15.02	$36,198.20	165,835
12/29/2022	Dipal Doshi	CEO	Sell	400	$15.01	$6,004.00	168,245
12/27/2022	Dipal Doshi	CEO	Sell	9,669	$15.02	$145,228.38	173,166
12/8/2022	Kory James Wentworth	CFO	Sell	4,550	$18.95	$86,222.50	16,509
12/5/2022	Kory James Wentworth	CFO	Sell	200	$18.05	$3,610.00	16,509
12/2/2022	Kory James Wentworth	CFO	Sell	2,910	$18.20	$52,962.00	16,509
11/28/2022	Dipal Doshi	CEO	Sell	2,000	$13.91	$27,820.00	182,835
10/31/2022	Nathan J Dowden	COO	Sell	2,100	$24.05	$50,505.00	45,283
10/27/2022	Dipal Doshi	CEO	Sell	2,000	$21.66	$43,320.00	184,835
10/25/2022	Nerissa Kreher	Insider	Sell	8,040	$20.88	$167,875.20	20,716
10/24/2022	Dipal Doshi	CEO	Sell	2,342	$19.30	$45,200.60	198,896
10/24/2022	Nathan J Dowden	COO	Sell	2,404	$19.30	$46,397.20	56,731
10/20/2022	Dipal Doshi	CEO	Sell	811	$18.01	$14,606.11	204,024
10/20/2022	Nathan J Dowden	COO	Sell	905	$18.07	$16,353.35	61,906
9/28/2022	Dipal Doshi	CEO	Sell	3,085	$15.23	$46,984.55	204,835
9/28/2022	Nerissa Kreher	Insider	Sell	3,122	$15.25	$47,610.50	20,716
9/26/2022	Dipal Doshi	CEO	Sell	3,083	$15.32	$47,231.56	212,339
9/26/2022	Nathan J Dowden	COO	Sell	1,544	$15.45	$23,854.80	62,811
9/26/2022	Nerissa Kreher	Insider	Sell	3,068	$15.33	$47,032.44	20,716
9/23/2022	Dipal Doshi	CEO	Sell	1,023	$15.07	$15,416.61	215,422
9/23/2022	Nathan J Dowden	COO	Sell	1,018	$15.07	$15,341.26	64,355
9/23/2022	Nerissa Kreher	Insider	Sell	939	$15.09	$14,169.51	20,716
9/21/2022	Dipal Doshi	CEO	Sell	3,402	$15.12	$51,438.24	216,445
9/21/2022	Nathan J Dowden	COO	Sell	3,275	$15.13	$49,550.75	65,373
9/21/2022	Nerissa Kreher	Insider	Sell	3,341	$15.08	$50,382.28	20,716
9/15/2022	Dipal Doshi	CEO	Sell	200	$15.04	$3,008.00	219,847
9/15/2022	Nathan J Dowden	COO	Sell	100	$15.01	$1,501.00	68,648
9/15/2022	Nerissa Kreher	Insider	Sell	106	$15.01	$1,591.06	20,716
9/9/2022	Nerissa Kreher	Insider	Sell	800	$15.07	$12,056.00	20,716
9/8/2022	Dipal Doshi	CEO	Sell	1,100	$15.16	$16,676.00	220,735
9/8/2022	Nathan J Dowden	COO	Sell	912	$15.15	$13,816.80	69,613
8/31/2022	Dipal Doshi	CEO	Sell	171	$12.00	$2,052.00	206,710
8/29/2022	Dipal Doshi	CEO	Sell	1,639	$12.88	$21,110.32	207,071
8/25/2022	Kory James Wentworth	CFO	Sell	1,551	$14.18	$21,993.18	10,986
8/23/2022	Kory James Wentworth	CFO	Sell	2,909	$13.09	$38,078.81	14,538
8/18/2022	Kory James Wentworth	CFO	Sell	200	$13.00	$2,600.00	20,221
8/16/2022	Kory James Wentworth	CFO	Sell	200	$13.00	$2,600.00	20,441
7/27/2022	Dipal Doshi	CEO	Sell	2,000	$12.00	$24,000.00	208,710
6/27/2022	Dipal Doshi	CEO	Sell	4,000	$12.00	$48,000.00	210,710
6/27/2022	Nathan J Dowden	COO	Sell	7,714	$13.00	$100,282.00	64,893
6/6/2022	Bros. Advisors Lp Baker	Major Shareholder	Buy	38,304	$6.41	$245,528.64	4,501,658
6/2/2022	Bros. Advisors Lp Baker	Major Shareholder	Buy	2,643	$5.82	$15,382.26	4,467,393
5/23/2022	Bros. Advisors Lp Baker	Major Shareholder	Buy	7,837	$5.99	$46,943.63	4,443,719
5/20/2022	Bros. Advisors Lp Baker	Major Shareholder	Buy	16,849	$5.84	$98,398.16	4,436,709
5/18/2022	Bros. Advisors Lp Baker	Major Shareholder	Buy	34,433	$6.00	$206,598.00	4,421,689
5/16/2022	Bros. Advisors Lp Baker	Major Shareholder	Buy	19,000	$5.83	$110,770.00	4,374,493
1/12/2022	John F. Crowley	Director	Buy	5,000	$9.71	$48,550.00

Elon to Transform U.S. Economy?

From Porter & Company | Ad

One company holds a near-total monopoly on it.

SEC Filings (Institutional Ownership Changes) for Entrada Therapeutics (NASDAQ:TRDA)

86.39% of Entrada Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Entrada Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/7/2024	SG Americas Securities LLC	7,687	$0.11M	0.0%	-34.4%	0.023%
4/30/2024	Allspring Global Investments Holdings LLC	14,763	$0.21M	0.0%	+427.6%	0.044%
4/25/2024	New York State Teachers Retirement System	1,915	$27K	0.0%	N/A	0.006%
4/18/2024	Allspring Global Investments Holdings LLC	14,763	$0.21M	0.0%	+427.6%	0.044%
3/5/2024	Wellington Management Group LLP	1,047,780	$15.81M	0.0%	+0.2%	3.140%
2/14/2024	72 Investment Holdings LLC	172,600	$2.61M	11.6%	-66.1%	0.517%
2/13/2024	Tower Research Capital LLC TRC	5,780	$87K	0.0%	+476.3%	0.017%
2/6/2024	Swiss National Bank	23,000	$0.35M	0.0%	-8.7%	0.069%
1/30/2024	Strs Ohio	24,100	$0.36M	0.0%	+792.6%	0.072%
1/12/2024	SG Americas Securities LLC	11,714	$0.18M	0.0%	+27.7%	0.035%
12/1/2023	Wellington Management Group LLP	1,045,652	$16.52M	0.0%	+2.6%	3.134%
11/15/2023	Redmile Group LLC	1,284,000	$20.29M	1.0%	-2.1%	3.848%
11/14/2023	Corton Capital Inc.	10,485	$0.17M	0.1%	-42.0%	0.031%
10/27/2023	Allspring Global Investments Holdings LLC	2,798	$44K	0.0%	N/A	0.008%
10/27/2023	TD Asset Management Inc	119,254	$1.88M	0.0%	+100.0%	0.359%
10/13/2023	SG Americas Securities LLC	9,174	$0.15M	0.0%	N/A	0.028%
9/21/2023	Barclays PLC	6,440	$97K	0.0%	-37.0%	0.019%
8/11/2023	Nan Fung Group Holdings Ltd	49,082	$0.74M	0.5%	-33.3%	0.148%
8/4/2023	American International Group Inc.	10,299	$0.16M	0.0%	N/A	0.031%
7/31/2023	Strs Ohio	2,700	$40K	0.0%	N/A	0.008%
5/11/2023	CHI Advisors LLC	56,374	$0.82M	0.2%	N/A	0.170%
5/9/2023	Y Intercept Hong Kong Ltd	10,188	$0.15M	0.0%	N/A	0.031%
2/14/2023	683 Capital Management LLC	10,355	$0.14M	0.0%	N/A	0.033%
2/9/2023	Citigroup Inc.	51,042	$0.69M	0.0%	+3,124.4%	0.163%
2/8/2023	Swiss National Bank	26,500	$0.36M	0.0%	N/A	0.084%
11/15/2022	TCG Crossover Management LLC	642,189	$10.12M	3.0%	-3.2%	2.045%
11/15/2022	Laurion Capital Management LP	199,066	$3.14M	0.0%	+54.2%	0.634%
11/10/2022	Nan Fung Group Holdings Ltd	141,593	$2.23M	1.4%	-18.4%	0.451%
11/7/2022	TD Asset Management Inc.	59,496	$0.93M	0.0%	+3.2%	0.189%
8/15/2022	Laurion Capital Management LP	129,066	$1.57M	0.0%	N/A	0.411%
5/27/2022	Walleye Capital LLC	44,652	$0.42M	0.0%	N/A	0.142%
5/5/2022	New York State Common Retirement Fund	4,880	$46K	0.0%	N/A	0.016%
2/18/2022	TCG Crossover Management LLC	663,694	$11.36M	5.3%	N/A	2.126%
2/14/2022	Redmile Group LLC	1,954,420	$33.46M	0.8%	N/A	6.262%
2/14/2022	72 Investment Holdings LLC	509,024	$8.71M	7.7%	N/A	1.631%
2/14/2022	Suvretta Capital Management LLC	106,000	$1.82M	0.0%	N/A	0.340%
2/14/2022	Ghisallo Capital Management LLC	15,000	$0.26M	0.0%	N/A	0.048%
2/14/2022	Goldman Sachs Group Inc.	7,626,182	$130.56M	0.0%	N/A	24.433%
2/11/2022	MPM Asset Management LLC	4,425,784	$75.77M	16.4%	N/A	14.179%
2/10/2022	TD Asset Management Inc.	57,675	$0.99M	0.0%	N/A	0.185%
2/8/2022	Northern Trust Corp	79,483	$1.36M	0.0%	N/A	0.255%
2/3/2022	5AM Venture Management LLC	4,408,379	$75.47M	14.2%	N/A	14.124%

Data available starting January 2016

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $14.05

$13.52

$14.25

50 Day Range

MA: $13.02

$11.58

$14.35

52 Week Range

Now: $14.05

$10.62

$18.44

Volume

57,449 shs

Average Volume

75,914 shs

Market Capitalization

$473.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Entrada Therapeutics?: Entrada Therapeutics' top insider shareholders include:
Bros Advisors Lp Baker (Major Shareholder)
Dipal Doshi (CEO)
Natarajan Sethuraman (Insider)
Nathan J Dowden (COO)
Peter S Kim (Director)
Kory James Wentworth (CFO)
Nerissa Kreher (Insider)
Learn More about top insider investors at Entrada Therapeutics.
Who are the major institutional investors of Entrada Therapeutics?: Entrada Therapeutics' top institutional shareholders include:
Allspring Global Investments Holdings LLC — 0.04%
Allspring Global Investments Holdings LLC — 0.04%
SG Americas Securities LLC — 0.02%
New York State Teachers Retirement System — 0.01%
Learn More about top institutional investors of Entrada Therapeutics stock.
Which institutional investors are selling Entrada Therapeutics stock?: Within the last quarter, TRDA stock was sold by these institutional investors:
SG Americas Securities LLC
Within the last year, company insiders that have sold Entrada Therapeutics company stock include:
Bros Advisors Lp Baker (Major Shareholder)
Dipal Doshi (CEO)
Natarajan Sethuraman (Insider)
Nathan J Dowden (COO)
Peter S Kim (Director)
Learn More investors selling Entrada Therapeutics stock.
Which institutional investors are buying Entrada Therapeutics stock?: In the previous quarter, TRDA stock was bought by institutional investors including:
Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC
New York State Teachers Retirement System
Within the previous year, these company insiders have bought Entrada Therapeutics stock:
Bros Advisors Lp Baker (Major Shareholder)
Dipal Doshi (CEO)
Learn More investors buying Entrada Therapeutics stock.